[go: up one dir, main page]

PE20100561A1 - Derivados de piridazina como agentes inhibidores de esteaorilcoa desaturasa - Google Patents

Derivados de piridazina como agentes inhibidores de esteaorilcoa desaturasa

Info

Publication number
PE20100561A1
PE20100561A1 PE2010000343A PE2010000343A PE20100561A1 PE 20100561 A1 PE20100561 A1 PE 20100561A1 PE 2010000343 A PE2010000343 A PE 2010000343A PE 2010000343 A PE2010000343 A PE 2010000343A PE 20100561 A1 PE20100561 A1 PE 20100561A1
Authority
PE
Peru
Prior art keywords
alkyl
pyridazine
piperazin
amide
desaturase
Prior art date
Application number
PE2010000343A
Other languages
English (en)
Inventor
Nagasree Chakka
Mikhail Chafeev
Sultan Chowdhury
Jian-Min Fu
Duanjie Hou
Rajender Kamboj
Vishnumurthy Kodumuru
Shifeng Liu
Vandna Raina
Shaoyi Sun
Serguei Sviridov
Michael D Winther
Zaihui Zhang
Heinz W Gschwend
Melwyn Abreo
Mark W Holladay
Wenbao Li
Sengen Sun
Chi Tu
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of PE20100561A1 publication Critical patent/PE20100561A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A COMPUESTOS DERIVADOS DE PIRIDAZINA DE FORMULA (Ia), DONDE X E Y SON 1; W ES C(O)NR1, NR1C(O), ENTRE OTROS; V ES C(O), C(O)O, C(S), ENTRE OTROS; R1 ES H, ALQUILO C1-C6, ALQUILO C2-C6, ENTRE OTROS; R2 ES ALQUILO C1-C12, ALQUENILO C2-C12, ENTRE OTROS; R3 ES ALQUILO C1-C12, ALQUENILO C2-C12, ALCOXI C1-C12, ENTRE OTROS; R4 Y R5 SON H, FLUORO, CLORO, METILO, METOXI, ENTRE OTROS; R6, R6a, R7, R7a, R8, R8a, R9 Y R9a SON H O ALQUILO C1-C3; R10 ES H O ALQUILO C1-C3; R12 ES H O ALQUILO C1-C6. SON COMPUESTOS PREFERIDOS: ACIDO 6-[4-(2-ETILBUTIRIL)PIPERAZIN-1-IL]PIRIDAZINA-3-CARBOXILICO(2-CICLOPROPILETIL)AMIDA, ACIDO 6-[4-(3,3,3-TRIFLUORO-2-METIL-2-TRIFLUOROMETILPROPIONIL)PIPERAZIN-1-IL]PIRIDAZINA-3-CARBOXILICO(2-CICLOPROPILETIL)AMIDA, ACIDO 6-[4-(4,4,4-TRIFLUORO-3-TRIFLUOROMETILBUT-2-ENOIL)-PIPERAZIN-1-IL]PIRIDAZINA-3-CARBOXILICO(2-CICLOPROPIL-ETIL)AMIDA, ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE ESTEAORIL-COA DESATURASA (SDC), PREFERENTEMENTE, SDC1 Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON LOS NIVELES ELEVADOS DE LIPIDOS, ENFERMEDADES CARDIOVASCULARES, DIABETES, OBESIDAD, SINDROME METABOLICO, ENTRE OTROS
PE2010000343A 2005-02-09 2006-02-09 Derivados de piridazina como agentes inhibidores de esteaorilcoa desaturasa PE20100561A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/055,034 US7754711B2 (en) 2003-07-30 2005-02-09 Pyridazine derivatives and their use as therapeutic agents

Publications (1)

Publication Number Publication Date
PE20100561A1 true PE20100561A1 (es) 2010-08-25

Family

ID=36646207

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2006000153A PE20061065A1 (es) 2005-02-09 2006-02-09 Derivados de piridazina como agentes inhibidores de esteaoril-coa desaturasa
PE2010000343A PE20100561A1 (es) 2005-02-09 2006-02-09 Derivados de piridazina como agentes inhibidores de esteaorilcoa desaturasa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2006000153A PE20061065A1 (es) 2005-02-09 2006-02-09 Derivados de piridazina como agentes inhibidores de esteaoril-coa desaturasa

Country Status (16)

Country Link
US (1) US7754711B2 (es)
EP (1) EP1851205B1 (es)
JP (1) JP5114212B2 (es)
CN (2) CN102600162A (es)
AR (1) AR052902A1 (es)
AT (1) ATE553096T1 (es)
AU (2) AU2006212763A1 (es)
BR (1) BRPI0606817A2 (es)
CA (1) CA2597069C (es)
ES (1) ES2385577T3 (es)
GT (1) GT200600045A (es)
MX (1) MX2007009593A (es)
MY (1) MY141939A (es)
PE (2) PE20061065A1 (es)
TW (1) TWI320316B (es)
WO (1) WO2006086447A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7759348B2 (en) * 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
AR051090A1 (es) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR051093A1 (es) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
CN101090724A (zh) * 2004-09-20 2007-12-19 泽农医药公司 用于抑制人硬脂酰CoA去饱和酶的吡啶衍生物
US7547698B2 (en) * 2004-09-20 2009-06-16 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD)
MX2007003332A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
AU2005286728A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1830837B1 (en) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
JP5149009B2 (ja) * 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
MX2007003325A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
EP2029138A1 (en) * 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
CN101506203B (zh) 2006-08-24 2013-10-16 诺瓦提斯公司 治疗代谢病、心血管病和其他病症的作为硬脂酰辅酶a脱饱和酶(scd)抑制剂的2-(吡嗪-2-基)-噻唑和2-(1h-吡唑-3-基)-噻唑衍生物及相关化合物
WO2008029266A1 (en) * 2006-09-08 2008-03-13 Glenmark Pharmaceuticals S.A. Stearoyl coa desaturase inhibitors
WO2008046226A1 (en) * 2006-10-20 2008-04-24 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2007323193A1 (en) * 2006-11-20 2008-05-29 Glenmark Pharmaceuticals S.A. Acetylene derivatives as Stearoyl CoA Desaturase inhibitors
TW200826936A (en) 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AR064965A1 (es) 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
US8575167B2 (en) 2007-02-06 2013-11-05 Takeda Pharmaceutical Company Limited Spiro compounds having stearoyl-CoA desaturase action
ES2571533T3 (es) * 2007-04-27 2016-05-25 Purdue Pharma Lp Antagonistas de TRPV1 y usos de los mismos
WO2008157844A1 (en) * 2007-06-21 2008-12-24 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
WO2010075356A1 (en) * 2008-12-23 2010-07-01 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
AU2010215035B2 (en) 2009-02-17 2014-06-12 Merck Canada Inc. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
WO2011011872A1 (en) 2009-07-28 2011-02-03 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
WO2011030312A1 (en) 2009-09-10 2011-03-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
ES2620528T3 (es) 2011-06-22 2017-06-28 Purdue Pharma Lp Antagonistas de TRPV1 que incluyen un sustituyente dihidroxi y usos de los mismos
EP2852387A2 (en) 2012-05-22 2015-04-01 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Selective inhibitors of undifferentiated cells
PH12018500586B1 (en) 2015-09-16 2023-08-11 Organovo Inc Farnesoid x receptor agonists and uses thereof
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
AU2018205275B2 (en) 2017-01-06 2024-05-02 Janssen Pharmaceutica Nv Methods for the treatment of neurological disorders
CN110637015B (zh) 2017-03-15 2024-04-02 奥加诺沃公司 法尼醇x受体激动剂及其用途
JP7174709B2 (ja) 2017-03-15 2022-11-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
AU2019238326B2 (en) 2018-03-23 2025-03-06 Janssen Pharmaceutica Nv Compounds and uses thereof
FI3852748T3 (fi) 2018-09-18 2025-10-22 Lilly Co Eli Farnesoid x -reseptoriagonisteja ja niiden käyttötapoja
KR20220007845A (ko) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
US20230078764A1 (en) * 2019-03-22 2023-03-16 Yumanity Therapeutics, Inc. Compounds and uses thereof
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
WO2021188695A1 (en) 2020-03-18 2021-09-23 Metacrine, Inc. Formulations of a farnesoid x receptor agonist

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
MY104343A (en) 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
US5883094A (en) * 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
ES2162235T3 (es) * 1996-01-15 2001-12-16 Janssen Pharmaceutica Nv Piridazinaminas inhibidoras de la angiogenesis.
DE19614204A1 (de) 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO1999000386A1 (en) 1997-06-27 1999-01-07 Resolution Pharmaceuticals Inc. Dopamine d4 receptor ligands
US6677452B1 (en) 1999-09-30 2004-01-13 Lion Bioscience Ag Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof
ATE475718T1 (de) * 2000-02-24 2010-08-15 Xenon Pharmaceuticals Inc Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
DE60130771T2 (de) 2000-07-27 2008-07-17 Eli Lilly And Co., Indianapolis Substituierte heterocyclische amide
CA2430987A1 (en) 2000-09-26 2002-04-04 Xenon Genetics, Inc. Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
WO2002102778A1 (en) 2001-06-15 2002-12-27 Yamanouchi Pharmaceutical Co., Ltd. Phenylpyridine carbonyl piperazine derivative
FR2827604B1 (fr) * 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
CN1628109A (zh) * 2002-02-05 2005-06-15 诺沃挪第克公司 新颖的芳基－与杂芳基－哌嗪
OA12790A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv New inhibitors of histone deacetylase.
CN1305850C (zh) 2002-03-13 2007-03-21 詹森药业有限公司 作为组蛋白脱乙酰酶新颖抑制剂的磺酰基氨基衍生物
ES2329356T3 (es) * 2002-06-12 2009-11-25 Chemocentryx, Inc. Derivados de piperazina 1-arilo-4-sustituidos utilizados como antagonistas de ccr1 para el tratamiento de enfermedades inflamatorias e inmunitarias.
US7262194B2 (en) * 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20040024658A1 (en) 2002-08-05 2004-02-05 General Electric Company System and method for providing asset management and tracking capabilities
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
CN101693697A (zh) 2003-07-30 2010-04-14 泽农医药公司 哌嗪衍生物和它们作为治疗剂的用途
TWI345974B (en) * 2003-07-30 2011-08-01 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use in the inhibition of stearoyl-coa desaturase
ES2386353T3 (es) 2003-07-30 2012-08-17 Xenon Pharmaceuticals Inc. Derivados de piridazina y su uso como agentes terapéuticos
MX2007003325A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
CA2615045A1 (en) * 2005-07-20 2007-01-25 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase

Also Published As

Publication number Publication date
JP5114212B2 (ja) 2013-01-09
WO2006086447A3 (en) 2007-04-05
TWI320316B (en) 2010-02-11
BRPI0606817A2 (pt) 2009-07-14
GT200600045A (es) 2006-09-13
ES2385577T3 (es) 2012-07-26
CN101160289A (zh) 2008-04-09
AU2010227003B2 (en) 2012-06-14
JP2008530098A (ja) 2008-08-07
AU2006212763A1 (en) 2006-08-17
PE20061065A1 (es) 2006-12-01
ATE553096T1 (de) 2012-04-15
US7754711B2 (en) 2010-07-13
AR052902A1 (es) 2007-04-11
WO2006086447A2 (en) 2006-08-17
CA2597069A1 (en) 2006-08-17
EP1851205B1 (en) 2012-04-11
CN102600162A (zh) 2012-07-25
US20060009459A1 (en) 2006-01-12
TW200638935A (en) 2006-11-16
EP1851205A2 (en) 2007-11-07
MY141939A (en) 2010-07-30
MX2007009593A (es) 2007-10-16
CA2597069C (en) 2011-09-20
AU2010227003A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
PE20100561A1 (es) Derivados de piridazina como agentes inhibidores de esteaorilcoa desaturasa
PE20081135A1 (es) Derivados que contienen sulfamoilo y sus usos
PE20081354A1 (es) Compuestos de azaindolilo como inhibidores de mek
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
MX2011010647A (es) Analogos de isoxasol-3 (2h)-ona como agentes terapeuticos.
PE20051155A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
PE20091557A1 (es) Derivados de piridazina y su uso como agentes terapeuticos
CO6140053A2 (es) Proceso para fabricar 2-amino-5-halobenzamidas 3-sustituidas
PE20060215A1 (es) 4-fenilamino-quinazolin-6-il-amidas
MX2010007977A (es) Derivados de carboxamidas azabiciclicas, su preparacion y su aplicacion en terapeutica.
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
AR051839A1 (es) Metodo para preparar n-fenilpirazol -1- carboxamidas
EA200300777A1 (ru) N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов для fsad
PE20081596A1 (es) Derivados fluorinados de deferiprona
MA30694B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
PE20110424A1 (es) Isoindolonas que inhiben la cinasa mek
DK2091948T3 (da) Nye inhibitorer af glutaminylcyclase
RU2009149210A (ru) Ингибиторы днк-зависимой протеинкиназы (днк-пк)
EA200970161A1 (ru) Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt
TW200614983A (en) 5-substituted-2-phenylamino benzamides as MEK inhibitors
NO20085269L (no) 2-tioksantinderivater som fungerer som MPO-inhibitorer
MA30756B1 (fr) Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1
TW200716531A (en) Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia
WO2007088276A3 (fr) Derives de sulfonamides, leur preparation et leur application en therapeutique
CO5580821A2 (es) 4-cetolactamas y -lactonas 3-fenil-3-substituidas, espirociclicas

Legal Events

Date Code Title Description
FX Voluntary withdrawal